Beta Cell Biology Consortium (U01)

Post Date

August 14th 2009

Application Due Date

November 23rd 2009

Funding Opportunity Number

RFA-DK-09-011

CFDA Number(s)

93.847

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Food and Nutrition
Health

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) .

Funding

• Estimated Total Funding:

  $12000000

• Award Range:

  $None - $None

Grant Description

Purpose. The National Institute of Diabetes and Digestive and Kidney Diseases invite new U01 applications to participate in a consortium of investigators, the Beta Cell Biology Consortium (BCBC); www.betacell.org . The BCBC will work collaboratively to facilitate research in the following areas: 1) use cues from pancreatic development to directly differentiate pancreatic beta cells and islets from stem/progenitor cells for use in cell-replacement therapies for diabetes; 2) determine how to stimulate beta cell regeneration in the adult pancreas as a basis for improving beta cell mass in diabetic patients; 3) determine how to reprogram progenitor/adult cells into pancreatic beta-cells both in-vitro and in-vivo as a mean for developing cell-replacement therapies for diabetes; and 4) investigate the progression of human type-1 diabetes using patient-derived cells and tissues transplanted in humanized mouse models. The BCBC will be responsible for collaboratively generating the necessary reagents, mouse strains, antibodies, assays, protocols, technologies and validation assays that are beyond the scope of any single research effort proposed by the investigators. Mechanism of Support. This FOA will utilize the U01 grant mechanism. Funds Available and Anticipated Number of Awards. The total amount of funding that the NIDDK expects to award through this announcement in FY2010 is $12 million. The anticipated number of awards is 6-10. Although the financial plans of the NIDDK provide support for the first two years of this program, awards pursuant to this FOA, particularly in years 3 to 5 of the awards, are contingent upon the availability of funds.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-09-011.html